HALO Q2 revenue +48% to $481.0M, net income +39% to $229.9M

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~1 min read

Key Changes

• high

  $285M IPR&D expensed) adds second hyperconcentration platform (500 mg/mL biologic concentrations, single auto-injector delivery), diversifying beyond ENHANZE and Hypercon.

  MD&A: Surf Bio acquisition verify on EDGAR →
• high

  New ENHANZE collaborations with Incyte (INCA033989 + up to two additional targets), GSK (multiple oncology targets, first antibody-drug conjugate application), and undisclosed nucleic acid partner expand addressable therapeutic areas.

  MD&A: New ENHANZE collaborations verify on EDGAR →
• high

  CMS finalized 2028 IRA guidance preserving 13-year exclusivity for ENHANZE combination therapies, but proposed 2029+ rule would aggregate alternative-route formulations with same-holder products, potentially shortening exclusivity (final rule expected Fall 2026).

  Risk Factors: IRA fixed-combination drug policy verify on EDGAR →